# Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients

> **NCT03489616** · NA · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 45 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** rhGM-CSF
- **DRUG:** Pemetrexed
- **RADIATION:** Local Radiotherapy
- **DRUG:** Single agent

## Key facts

- **NCT ID:** NCT03489616
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-15
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489616, "Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03489616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*